Quantumzyme Corp lost $0.01 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a loss of $0.13 per diluted share. The table below carries 5 fiscal years, from 2016 to 2025, and the quarters Quantumzyme Corp has filed alongside them.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Quantumzyme Corp lost $0.01 per diluted share in fiscal year 2025.
Quantumzyme Corp (QTZM) reported a loss of $0.01 per diluted share in fiscal year 2024 and a loss of $0.01 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Quantumzyme Corp (QTZM) reported a loss of $0.13 per diluted share over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
Quantumzyme Corp (QTZM) reported $0.00 in diluted earnings per share in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Quantumzyme Corp (QTZM) reported on that line in every period on record.
